Chen Xu, Dong Dan-feng, Wu Yin-ying, Huang Hui-yun, Liang Jing, Li En-xiao
Department of Medical Oncology, the First Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an 710061, China.
Zhonghua Zhong Liu Za Zhi. 2009 Dec;31(12):916-9.
To analyze the clinical characteristics and survival data of 57 patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
The medical records of 57 patients with PTCL-NOS classified according to the revised REAL-WHO criteria, treated from Jan 1993 to Dec 2007 at the First and the Third affiliated Hospitals of Medical School of Xi'an Jiaotong University, were retrospectively evaluated by K-M univariate and COX multivariate analysis.
39 of the patients (68.4%) were males and 18 (31.6%) were females, aged 44 (3 - 88). Nine of the 57 patients (15.8%) were treated with chemo-radiotherapy, 43 (75.4%) with chemotherapy, 3 (5.3%) with radiotherapy, and 2 with supported treatment alone (2.5%). The overall response rate was 87.3%, with a complete remission (CR) rate of 60.0% in 55 evaluable cases. The 1-, 3-, and 5-year overall survival (OS) rates were 67.0%, 48.0% and 24.3%, respectively, with a median follow-up of 30.4 months (ranged 1-100 months). The median survival time (MST) was 36.0 months. Multivariate analysis showed that the prognostic index for T cell lymphoma (PIT) score was an independent prognostic factor for PTCL-NOS (P < 0.05), but bone marrow involvement, performance status, extranodal involvement, stage, B symptom were not independent prognostic factors.
Although conventional chemotherapy yields a high response rate for PTCL-NOS, the long-term survival is still low and further investigation for optional treatment is needed.
分析57例外周T细胞淋巴瘤,非特殊类型(PTCL-NOS)患者的临床特征及生存数据。
回顾性评估1993年1月至2007年12月在西安交通大学医学院第一附属医院和第三附属医院按照修订的REAL-WHO标准分类治疗的57例PTCL-NOS患者的病历,采用K-M单因素和COX多因素分析。
57例患者中男性39例(68.4%),女性18例(31.6%),年龄44岁(3-88岁)。57例患者中9例(15.8%)接受了化疗联合放疗,43例(75.4%)接受了化疗,3例(5.3%)接受了放疗,2例仅接受了支持治疗(2.5%)。总缓解率为87.3%,55例可评估病例的完全缓解(CR)率为60.0%。1年、3年和5年总生存率(OS)分别为67.0%、48.0%和24.3%,中位随访时间为30.4个月(范围1-100个月)。中位生存时间(MST)为36.0个月。多因素分析显示,T细胞淋巴瘤预后指数(PIT)评分是PTCL-NOS的独立预后因素(P<0.05),但骨髓受累、体能状态、结外受累、分期、B症状不是独立预后因素。
尽管传统化疗对PTCL-NOS有较高的缓解率,但长期生存率仍较低,需要进一步研究选择更佳的治疗方案。